Moleculin Biotech names new director
6 October 2020 -

Moleculin Biotech Inc, (Nasdaq: MBRX), a clinical stage pharmaceutical company, has named Elizabeth (Liz) Cermak as its new director, it was reported on Monday.

The new director has held various board positions in the healthcare space, including Que Oncology and Clarus Therapeutics Inc where she held the position of independent board director. She was previously an independent board director at SteadyMed Therapeutics and served on the board of a local non-profit, Ocean Ridge Charities Association Inc. She was chief commercial officer and executive vice president at POZEN and has worked at Johnson & Johnson for 25 years, serving most recently as world-wide vice president Personal Products Franchise and vice president Professional Sales & Marketing. She has also headed the Johnson & Johnson US Women's Health pharmaceuticals business.

Walter Klemp, Moleculin chairman and CEO, said, 'We are pleased to welcome Liz Cermak, who brings nearly four decades of expertise in the healthcare space and a proven track record of advancing clinical development, and commercialising and licensing drugs, to our board of directors. We believe Liz' extensive leadership experience in overseeing drugs through commercialisation and licensing to well-respected big pharmaceutical companies will prove invaluable. As a highly seasoned executive with decades of industry experience, we look forward to Liz' counsel in driving the development of both our oncology and infectious disease pipelines.'